APGE Stock Risk & Deep Value Analysis
Apogee Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About APGE Stock
We analyzed Apogee Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran APGE through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
APGE Risk Analysis & Red Flags
What Could Go Wrong
The primary risk is that zumilokibart (APG777) fails to replicate its 'best-in-class' efficacy or favorable safety profile in larger and longer Phase 3 trials, leading to significant delays, increased development costs, or outright rejection by regulatory bodies, thereby jeopardizing the potential for multi-billion dollar peak sales in the atopic dermatitis market which is the cornerstone of its current $6.5B valuation.
Risk Matrix
Overall
Aggressive
Financial
Low-Medium
Market
Medium
Competitive
High
Execution
Medium
Regulatory
High
Red Flags
- ⚠
CEO Michael Thomas Henderson sold 20,000 shares for approximately $1.77 million on April 8, 2026, which occurred before the recent positive clinical data and financing news.
- ⚠
The company is pre-revenue and deeply unprofitable, reporting Q1 2026 EPS of -$1.06, with its valuation entirely dependent on the successful, costly, and lengthy process of clinical development.
- ⚠
High reliance on a single lead asset, APG777, for the majority of its near-term valuation, with other pipeline candidates in earlier, higher-risk development stages.
Upcoming Risk Events
- 📅
Negative or unexpected safety events reported in APG777 Phase 3 trials (Q4 2026 onwards): Could severely impact clinical development timeline and market perception.
- 📅
Emergence of a superior or equally effective competitor in the IL-13 pathway for atopic dermatitis (Ongoing, particularly from large pharma rivals like Sanofi/Regeneron): Could dilute APG777's market share potential upon commercialization.
When to Reconsider
- 🚪
Announcement of significant adverse events or failure to meet primary endpoints in APG777's Phase 3 trials, leading to a substantial setback or termination.
- 🚪
Cash and cash equivalents (which were robust post-Blackstone deal) fall below $500M without a clear and non-dilutive financing plan to sustain operations for at least 12 months.
Unlock APGE Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Apogee Therapeutics Inc (APGE) Do?
Market Cap
$6.66B
Sector
Healthcare
Industry
Biotechnology
Employees
196
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Visit Apogee Therapeutics Inc WebsiteInvestment Thesis
If zumilokibart (APG777) successfully demonstrates best-in-class efficacy and a favorable safety profile in its pivotal Phase 3 trials, enabling BLA submission and eventual commercialization, then Apogee could achieve multi-billion dollar peak sales in the atopic dermatitis market. This is bullish because the $1.3 billion non-dilutive financing from Blackstone significantly de-risks the financial runway through these critical clinical milestones, allowing for sustained R&D investment and a substantial market re-rating as it approaches commercialization with a differentiated product.
Is APGE Stock Undervalued?
Unlock the full AI analysis for APGE
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
APGE Price Targets & Strategy
12-Month Target
$130.00
Bull Case
$160.00
Bear Case
$65.00
Valuation Basis
Implied 0.25x Peak Sales on estimated $5B-$6B risk-adjusted peak sales for APG777 by 2030, discounted for development risk.
Entry Strategy
Dollar-cost average between $80-$85 (near recent support) if momentum temporarily wanes, otherwise buy on strength above $87.00.
Exit Strategy
Take 50% profit at $130 (average analyst high target), stop loss at $65.00 (below recent lows and major support).
Portfolio Allocation
7-10% for aggressive risk tolerance.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is APGE Financially Healthy?
Valuation
P/E Ratio
2.40
Forward P/E
-0.80
EV/EBITDA
-7.10
PEG Ratio
-0.04
Price/Book
12.80
Profitability
Return on Equity
-32.64%
EPS
$-4.33
Balance Sheet
Current Ratio
18.55
Quick Ratio
18.29
Cash & Equivalents
$1.20B
Cash Flow
Operating Cash Flow
-$356.00M
Free Cash Flow
-$372.00M
EBITDA
-$401.00M
Other
Beta (Volatility)
0.52
Does APGE Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The durability of Apogee's moat hinges on the strength and breadth of its patent portfolio for zumilokibart, its ability to consistently demonstrate superior efficacy and safety in subsequent clinical trials, and its capacity to establish a strong market position upon launch before its key patents begin to expire.
Moat Erosion Risks
- •Loss of key patent protection or successful challenges to existing patents on APG777, leading to early generic/biosimilar entry.
- •Development and commercialization of new, more effective or convenient therapies by competitors that could diminish APG777's clinical differentiation.
APGE Competitive Moat Analysis
Sign up to see competitive advantages
APGE Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bullish, primarily driven by the recent positive Phase 2 data for APG777 and the de-risking Blackstone financing deal.
Institutional Sentiment
Positive, with a 'Moderate Buy' consensus from analysts, high average price targets (up to $160), and recent new 'Buy' coverage from Rothschild & Co Redburn.
Insider Activity (Form 4)
CEO Michael Thomas Henderson sold 20,000 shares on April 8, 2026, for an approximate value of $1.77 million.
Options Flow
Normal options activity (no specific unusual activity data provided).
Earnings Intelligence
Next Earnings
Estimated late July / early August 2026 (for Q2 2026 results)
Surprise Probability
Medium
Historical Earnings Pattern
As a relatively new public clinical-stage biotech, a clear historical pattern for stock price reaction to earnings is not yet established; however, significant clinical or financial updates often lead to high volatility.
Key Metrics to Watch
Competitive Position
Top Competitor
Sanofi (SNY) / Regeneron Pharmaceuticals (REGN) with Dupixent
Market Share Trend
Not applicable (pre-commercial); aims to gain significant share in the moderate-to-severe atopic dermatitis market upon approval.
Valuation vs Peers
Trading at a premium to many earlier-stage clinical biotechs due to strong Phase 2 data and significant financing, but a discount relative to the potential peak sales of an approved best-in-class biologic.
Competitive Advantages
- •Strong Phase 2 clinical data for APG777 (zumilokibart) suggesting potential for best-in-class efficacy and safety profile in atopic dermatitis.
- •Robust, non-dilutive strategic financing from Blackstone Life Sciences provides significant financial runway through critical development stages.
- •Targeting a validated, high-growth IL-13 pathway with a potentially differentiated molecule.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive APGE Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings Report (estimated late July/early August 2026): Focus on cash burn rate, R&D expenses, and updates on APG777 Phase 3 planning.
- •Update on APG777 Phase 3 design & initiation timeline (Q3 2026): Specific announcement regarding pivotal trial protocol and start date.
Medium-Term (6-18 months)
- •First patient dosed in APG777 Phase 3 trial for atopic dermatitis (Q4 2026 / Q1 2027): Operational milestone validating progress towards pivotal data.
- •Mid-stage clinical data for APG990 (for asthma) or APG825 (for EoE) (H1 2027): Diversifies pipeline validation and market potential beyond AD.
Long-Term (18+ months)
- •Topline data readout from APG777 Phase 3 trial in atopic dermatitis (H2 2028 - H1 2029): This would confirm best-in-class efficacy/safety, enabling BLA submission and substantial re-rating.
- •Commercial launch of zumilokibart (APG777) for atopic dermatitis (2030): First revenue generation from a potential multi-billion dollar blockbuster asset.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for APGE?
- ✓
Watch for specific dates and updates on APG777 Phase 3 trial initiation, patient enrollment rates, and interim analyses if reported.
- ✓
Monitor quarterly cash burn rates to ensure alignment with the extended financing runway and continued operational efficiency.
- ✓
Watch for any announcements of new clinical programs or data readouts for earlier-stage pipeline assets (e.g., APG990, APG825) as risk diversification.
Bull Case Analysis
Sign up free to see the bull case
Competing with APGE
See how Apogee Therapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Apogee Therapeutics Inc APGE | $6.7B | 9.6 | 2.4 | $9.8M | — | — | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Apogee Therapeutics Inc Makes Money
Apogee Therapeutics Inc. is a clinical-stage biotechnology company focused on discovering, developing, and potentially commercializing novel antibody therapeutics for inflammatory and immunological diseases. The company currently generates no revenue, relying on investor capital and strategic financing to fund its extensive research and development activities, particularly the costly clinical trials required to prove a drug's safety and efficacy. Its core business model is to develop groundbreaking drugs like zumilokibart (APG777) through all clinical phases, secure regulatory approvals, and then commercialize these high-value products to generate significant revenue from drug sales or through partnerships and licensing.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Apogee Therapeutics Inc (APGE)?
As of June 16, 2026, Apogee Therapeutics Inc has a DVR Score of 9.6 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Apogee Therapeutics Inc?
Apogee Therapeutics Inc's market capitalization is approximately $6.7B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Apogee Therapeutics Inc use?
APGE is the ticker symbol for Apogee Therapeutics Inc. The company trades on the NGM.
What is the risk level for APGE stock?
Our analysis rates Apogee Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of APGE?
Apogee Therapeutics Inc currently has a price-to-earnings (P/E) ratio of 2.4. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
How often is the APGE DVR analysis updated?
Our AI-powered analysis of Apogee Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 16, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for APGE (Apogee Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.